Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models.

  title={Understanding Central Nervous System Effects of Deliriant Hallucinogenic Drugs through Experimental Animal Models.},
  author={Andrey D. Volgin and Oleg A. Yakovlev and Konstantin A. Demin and Polina A. Alekseeva and Evan J. Kyzar and Christopher Collins and David E. Nichols and Allan V. Kalueff},
  journal={ACS chemical neuroscience},
  volume={10 1},
Hallucinogenic drugs potently alter human behavior and have a millennia-long history of use for medicinal and religious purposes. Interest is rapidly growing in their potential as CNS modulators and therapeutic agents for brain conditions. Antimuscarinic cholinergic drugs, such as atropine and scopolamine, induce characteristic hyperactivity and dream-like hallucinations and form a separate group of hallucinogens known as "deliriants". Although atropine and scopolamine are relatively well… 

DARK Classics in Chemical Neuroscience: Atropine, Scopolamine, and Other Anticholinergic Deliriant Hallucinogens.

Given the growing clinical importance of anti-M deliriant hallucinogens, the use and abuse, clinical importance, and the growing value in preclinical (experimental) animal models relevant to modeling CNS functions and dysfunctions are discussed.

Understanding the neurobiological effects of drug abuse: Lessons from zebrafish models

Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.

The mechanism of action of these compounds suggests a strong glutamatergic component that involves the facilitation of AMPA receptor function, which appears to be relevant to the antidepressant pharmacology of this new class of drugs.

Efavirenz as a psychotropic drug.

The psychotropic properties of efavirenz are reviewed, which are the most important adverse events associated with the drug and commonly result in treatment discontinuation, and whether prolonged exposure could lead to irreversible side effects is evaluated.

Signaling Mechanism Responsible for 5-HT2A Receptor Tolerance to Psychedelic Induced Head-Twitch Behavior in Mice

Part of the Animal Experimentation and Research Commons, Behavioral Neurobiology Commons, Behavior and Behavior Mechanisms Commons, Cellular and Molecular Physiology Commons, Disease Modeling

Scopolamine als bestanddeel van een magistrale bereiding als zeldzame oorzaak van visuele hallucinaties

A 40-year-old patient had a first episode of visual hallucinations caused by the abuse of a magistral preparation containing scopolamine as an active component, which caused an isolated hallucinosis instead of hallucinations as a consequence of an anticholinergic syndrome.

Self-Entropic Broadening Theory: Toward a New Understanding of Self and Behavior Change Informed by Psychedelics and Psychosis

The extremes of human experiences, such as those occasioned by classic psychedelics and psychosis, provide a rich contrast for understanding how components of these experiences impact well-being. In



Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models.

This study discusses psychedelic medicine as well as the behavioral and toxicological effects of hallucinogenic drugs in zebrafish, and emphasizes this aquatic organism as a model ideally suited to assess both the potential toxic and therapeutic effects of major known classes of hallucinationsinogenic compounds.

Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds.

Recognizing the growing importance of hallucinogens in biological psychiatry, this work discusses hallucinogenic-induced phenotypes in zebrafish and evaluates their potential as efficient preclinical models of drug-induced states in humans.

Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles

A better understanding of these compounds might improve knowledge of the processes involved in consciousness, the neuropathology of depression, and potentially open up new pharmacological therapies, as well as improve safety and clinical application.

Clinical applications of hallucinogens: A review.

This review will present data on several classes of hallucinogens with a particular focus on psychedelics, entactogens, and dissociatives, for which clinical utility has been most extensively documented, with important ramifications for their potential therapeutic value.

Psychedelic Drugs in Biomedicine.

Animal models of serotonergic psychedelics.

The behavioral effects induced by psychedelic drugs in rodent models are reviewed, the translational potential of these findings are discussed, and areas where further research is needed to better understand the molecular mechanisms and neuronal circuits underlying their neuropsychological effects are defined.

Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology

Modern Clinical Research on LSD

  • M. Liechti
  • Psychology, Medicine
  • 2017
All modern clinical studies using the classic hallucinogen lysergic acid diethylamide in healthy subjects or patients in the last 25 years are reviewed herein and should contribute to further investigations of the therapeutic potential of LSD in psychiatry.

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders.